Last year, FDA approved the celecoxib oral solution Elyxyb from Dr. Reddy’s Laboratories as an acute treatment of migraine with or without aura in adults. Formerly known as DFN-15, Elyxyb is a novel selective inhibitor of cyclooxygenase-2.
The company received FDA approval for the drug in May 2020.
The company formulated the drug as an oral solution using a self-micro emulsifying drug delivery system to optimize solubility and bioavailability.
Filed Under: Drug Discovery and Development, Neurological Disease